Brief: Amarin Issues Statement Supporting FDA’S Action To Revise Labeling For Fenofibrate Drugs Reinforcing A Lack Of Cardiovascular Benefit
27/10/2025 13:28
Oct 27 (Reuters) - Amarin Corporation PLC AMRN.O: AMARIN ISSUES STATEMENT SUPPORTING FDA’S ACTION TO REVISE LABELING FOR FENOFIBRATE DRUGS REINFORCING A LACK OF CARDIOVASCULAR BENEFIT Source text: ID:nGNXr502D Further company coverage: AMRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amarin
See all newsAmarin Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Ireland's Amarin Q2 revenue falls on lower licensing payments
Amarin Corporation PLC expected to post a loss of 1 cent a share - Earnings Preview
US Supreme Court backs generic drugmaker in 'skinny label' patent case (updated)
US Supreme Court backs generic drugmaker in 'skinny label' patent case